NCT06747728 Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
| NCT ID | NCT06747728 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Zhengzhou University |
| Condition | Brain Glioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-03-01 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Glioblastoma (GBM) usually grows in a diffuse fashion and infiltrates the surrounding brain. The inability to completely excise the tumor often leads to tumor recurrence within a few months of the initial surgery, which ultimately results in the death of the GBM patient.GBM histologically appears to be a tumor of vascular origin characterized by necrosis and microvascular proliferation, and neoangiogenesis is a key factor in the growth and poor prognosis of GBM. Bevacizumab can inhibit the biological effects of VEGF, including the permeability and proliferation of blood vessels, as well as the migration and survival of endothelial cells, so as to inhibit tumor angiogenesis, growth and metastasis. The aim of this study is to evaluate the efficacy and safety of bevacizumab in the preoperative adjuvant treatment of patients with new-onset high-grade gliomas.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * Male or female. * Imaging diagnosis of high-grade glioma. * KPS score ≥60. Exclusion Criteria: * Prior treatment with anti-angiogenic targeted drugs; * Comorbid serious cardiac, pulmonary, hepatic, or renal disease; * History of an arterial/venous thrombotic event within 6 months prior to screening; * Combination of infectious diseases such as tuberculosis and viral hepatitis; * Comorbid infectious diseases such as tuberculosis, viral hepatitis, uncontrolled high blood pressure, bleeding disorders, and long-standing unhealed wounds or incompletely healed fractures; * Patients with a history of psychotropic substance abuse that cannot be stopped or patients with mental disorders; * Abnormal coagulation function, with bleeding tendency * Patients who, in the opinion of the investigator, are not suitable for inclusion in the study (e.g., pregnant and lactating women).
Contact & Investigator
Junkuan Wang, M.D.
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital of Zhengzhou University
Frequently Asked Questions
Who can join the NCT06747728 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06747728 currently recruiting?
Yes, NCT06747728 is actively recruiting participants. Contact the research team at wjkuan@sina.cn for enrollment information.
Where is the NCT06747728 trial being conducted?
This trial is being conducted at Zhengzhou, China.
Who is sponsoring the NCT06747728 clinical trial?
NCT06747728 is sponsored by The First Affiliated Hospital of Zhengzhou University. The principal investigator is Junkuan Wang, M.D. at The First Affiliated Hospital of Zhengzhou University. The trial plans to enroll 20 participants.